Singular Health Group Reports Expiry of 3.23 Million Unexercised Options at $0.10, Impacting Unquoted Securities

Details on the Expiry of 3,233,441 SHGAAB Options on 26 June 2026

In a company update filed on 1 July 2026, Singular Health Group confirmed that all 3,233,441 SHGAAB options expired on 26 June 2026 without any exercise or conversion into ordinary shares. These options had an exercise price of $0.10 each, requiring holders to pay that amount per option to convert. The lack of exercise suggests holders found no economic benefit at expiry, though the company did not provide commentary on market conditions or holder intentions.

Options typically lapse unexercised when the exercise price is unattractive compared to the market price or when holders choose not to act before expiry. No immediate share price impact was evident from public information. By not exercising, holders forfeited any remaining option value, and Singular Health Group did not receive capital from this security class. The company confirmed no payment was made for the cessation, consistent with standard treatment of expired options.

Quoted Ordinary Shares Remain Unchanged at 323,773,117

Since the SHGAAB options expired without conversion, no new ordinary shares were issued. The total number of fully paid quoted ordinary shares (ASX Code: SHG) remains at 323,773,117. This means the expiry did not dilute existing shareholders, unlike scenarios involving option exercises and share issuance.

This stability ensures the company’s market capitalisation calculation, as reported by ASX, remains unaffected by this event. Investors referencing valuation metrics such as earnings per share will see no numerical change following this expiry notification.

Effect of SHGAAB Expiry on Singular Health Group’s Unquoted Securities

Before expiry, the SHGAAB series accounted for 3,233,441 unquoted options within the company’s broader unquoted securities. With the lapse, this class now shows zero securities on issue and is removed from the active capital structure. This modestly decreases the theoretical fully diluted share count used by investors and analysts to evaluate potential dilution if all convertible instruments were exercised.

While the expiry is neutral to capital structure in the short term, it may indicate option holders did not perceive sufficient upside at the $0.10 exercise price. The company provided no additional context or commentary beyond the required regulatory disclosures in the Appendix 3H filing.

Remaining Unquoted Options Span Exercise Prices from $0.08 to $0.55

Following the SHGAAB expiry, Singular Health Group continues to have eleven classes of unquoted options and one class of performance rights outstanding. Exercise prices range from $0.08 to $0.55 per share, with expiry dates from August 2026 through November 2029. This range establishes a timeline of potential dilution events depending on share price performance and holder decisions.

The largest volume class is the SHGAAD series, comprising 17,562,500 options expiring 8 December 2027 at an exercise price of $0.08, the lowest strike price among remaining options and thus most likely to be in-the-money if the share price exceeds this level. Other significant tranches include the SHGAAI series (10,000,000 options at $0.25, expiring 15 April 2029) and SHGAAL series (10,000,000 options at $0.55, expiring 26 June 2028), both with higher exercise prices.

Upcoming Expiry of SHGAAC Options on 10 August 2026

With the SHGAAB series extinguished, the next key expiry is the SHGAAC series, consisting of 1,818,182 options at a $0.10 exercise price, set to expire on 10 August 2026. This represents the nearest upcoming unquoted security maturity for investors tracking Singular Health Group’s capital events.

Whether SHGAAC holders exercise depends on the share price at or before expiry. Full exercise would issue 1,818,182 new shares and raise $181,818.20 in gross proceeds. The company did not provide guidance on expected exercise rates for this or other option classes.

Performance Rights and Longer-Dated Options Reflect Ongoing Equity Incentives

Among unquoted securities, Singular Health Group holds 10,000,000 performance rights under code SHGAZ. Unlike options, performance rights have no cash exercise price and typically vest upon meeting performance milestones, converting into shares at no cost. This indicates an active equity incentive program, though vesting conditions were not detailed.

Additionally, the SHGAA series (6,000,000 options at $0.55, expiring 30 November 2029) and SHGAAI series (10,000,000 options at $0.25, expiring 15 April 2029) are the longest-dated instruments outstanding. These provide holders with extended time to benefit from potential share price appreciation but also represent possible dilution for long-term investors.

Overview of Singular Health Group’s Capital Structure Post-Expiry

After the SHGAAB expiry, the company’s fully diluted capital includes 323,773,117 quoted ordinary shares plus approximately 81,070,954 unquoted options and performance rights across twelve classes (excluding the now-zero SHGAAB class), as disclosed in the Appendix 3H filing.

Investors should note the issued capital figures are automatically generated and may not reflect real-time changes if other filings such as Appendix 2A, 3G, or 3H are concurrently processed by ASX. For accurate capital structure, cross-reference this filing with other recent capital-related disclosures by Singular Health Group. No additional pending capital changes were disclosed.

Regulatory Framework: Appendix 3H Reporting Obligations

The Appendix 3H form is an ASX listing rule requirement mandating prompt disclosure when securities cease to exist through expiry, cancellation, or other means. This ensures transparent, timely market information on changes to issued capital, aiding price discovery and investor decisions. Singular Health Group’s 1 July 2026 filing, covering the 26 June 2026 expiry, complies with this obligation.

For investors, such filings provide an ongoing audit trail of capital base evolution. Monitoring option expiries, exercises, and issuances via Appendix 3H and related forms enables market participants to model dilution scenarios and assess the company’s equity financing and incentive strategies. This filing is routine and does not indicate material operational or strategic changes.

Investor Considerations for Upcoming Capital Events

The immediate event to watch is the SHGAAC option expiry on 10 August 2026. Subsequent expiries include the SHGAAE series (7,727,272 options at $0.10 expiring 9 February 2027) and SHGAAF series (3,638,000 options at $0.15 expiring 25 July 2027), which will generate further Appendix 3H disclosures and either raise capital or simplify the capital structure through lapses.

Longer term, investors should monitor announcements on new option grants, performance right vesting, or capital raisings that could affect diluted share count. Operational progress, especially milestones related to its medical technology business, will influence whether in-the-money options are exercised or allowed to expire. This update contained no operational news, revenue data, or forward guidance, focusing solely on the required capital cessation disclosure.